Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.06 USD
Change Today -0.0005 / -0.87%
Volume 612.2K
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

international stem cell corp (ISCO) Key Developments

International Stem Cell Corporation Announces Consolidated Earnings Results for the Years Ended December 31, 2014

International Stem Cell Corporation announced consolidated earnings results for the years ended December 31, 2014. For the period, the company reported total revenue of $7,017,000 against $6,147,000 a year ago. Loss from operating activities was $8,680,000 against $7,546,000 a year ago. Loss before income taxes was $12,478,000 against $10,479,000 a year ago. Net loss was $12,478,000 against $10,479,000 a year ago. Net loss applicable to common stockholders was $12,478,000 against $10,479,000 a year ago. Net loss per basic &diluted share was $0.06 against $0.09 a year ago. invested $987,000 in capital and patent expenditures in 2014, up compared to $896,000 in the prior year.

International Stem Cell Corporation, Q4 2014 Earnings Call, Apr 01, 2015

International Stem Cell Corporation, Q4 2014 Earnings Call, Apr 01, 2015

International Stem Cell Corporation Auditor Raises 'Going Concern' Doubt

International Stem Cell Corporation filed its 10-K on Mar 30, 2015 for the period ending Dec 31, 2014. In this report its auditor, Mayer Hoffman McCann P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

International Stem Cell Corporation Receives Key Stem Cell Patent in Japan

International Stem Cell Corporation announced that the Japan Patent Office has granted ISCO's patent covering methods of making a bank of human stem cells from parthenogenetically activated eggs, significantly strengthening the company's intellectual property position and partnering ability in Japan. ISCO's patent covers a new method of creating stem cells that combine many of the benefits of embryonic stem cells with induced pluripotent stem cells and can be used to generate virtually unlimited quantities of human cells. The company is currently using this technology to develop treatments for a number of indications where cell therapy has been demonstrated to be effective but there is insufficient supply of safe, functional cells. Preclinical safety and efficacy data from the company's Parkinson's disease program was recently presented at the Society for Neuroscience annual meeting, and a Phase I/IIa clinical study in Parkinson's disease is anticipated to begin in the near future.

International Stem Cell Corporation Announces Completion of Cell Bank for Parkinson's Disease Clinical Trial

International Stem Cell Corporation announced that the company has completed manufacturing of the cell bank of clinical-grade human neural stem cells using its patented process for the recently announced phase 1/2a clinical trial in Parkinson's disease. The cell bank contains over 2.6 billion human cells, sufficient to meet the company's foreseeable clinical trial requirements. ISCO's master cell bank of human parthenogenetic neural stem cells (ISC-hpNSC) is produced in compliance with current good manufacturing practices (cGMPs) and the chemistry and manufacturing controls (CMC) discussed in the previously reported pre-IND meeting with the FDA. The cells are karyotypically normal hpNSCs and free of measurable contaminants of human or animal origin. The production of hpNSCs from undifferentiated pluripotent human parthenogenetic stem cells in the master cell bank uses qualified reagents and a standardized protocol developed by ISCO. The undifferentiated human stem cells are derived from the parthenogenetic line and were recently cleared by the FDA for use in clinical trials. Each batch of hpNSC is subjected to standardized quality control testing to ensure viability, sterility and appropriate cellular composition before clinical use. The existing master cell bank and current production scale are sufficient to supply anticipated product needs through pivotal clinical trials. The cell bank was produced at the company's GMP manufacturing facility located in Oceanside, Calif. ISC-hpNSCs are a novel therapeutic cellular product derived from the Company's proprietary human pluripotent stem cells. Neural stem cells are self-renewing multipotent cells that are precursors for the main cell types of the central nervous system. The ability of ISC-hpNSCs to differentiate into dopaminergic neurons and express brain-protecting neurotrophic factors offers a new opportunity for the treatment of Parkinson's disease. ISCO's preclinical program includes animal studies to assess the safety and tolerability of novel cell therapy as well as doses ranging efficacy to be used to design the first clinical trial in Parkinson's disease patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISCO:US $0.06 USD -0.0005

ISCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioheart Inc $0.0080 USD -0.0008
Cytori Therapeutics Inc $1.11 USD -0.03
Nuo Therapeutics Inc $0.19 USD -0.026
ReNeuron Group PLC 3.89 GBp +0.265
StemCells Inc $0.91 USD -0.0321
View Industry Companies
 

Industry Analysis

ISCO

Industry Average

Valuation ISCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 43.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERNATIONAL STEM CELL CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.